One in eight men will be diagnosed with prostate cancer in their lifetime, making it one of the most common forms of cancer among men. Additionally, prostate cancer can remain dormant for up to 20 years without showing any symptoms. This fact increases the likelihood that affected individuals may not realize they have the disease until too late. Prostate cancer screenings, including prostate-specific antigen (PSA) blood tests and digital rectal examinations (DREs), are available; however, research indicates that many individuals still lack adequate access to these tests.

To address this issue, the 119th United States Congress has reintroduced H.R. 1300, to require group health plans and issuers of group or individual health insurance to provide coverage for prostate cancer screenings without imposing cost-sharing requirements, such as co-payments, coinsurance, or deductibles. In support of this initiative, I will reintroduce a resolution to designate September 2025 as “Prostate Cancer Awareness Month” in Pennsylvania. This designation will serve as a reminder of the efforts needed to ensure that no one faces barriers to accessing these lifesaving tests.

I invite you to join me in co-sponsoring this resolution to raise awareness for the many individuals who are at risk of this silent but deadly disease.